Abstract:The current epidemic situation of coronavirus disease 2019 (COVID-19) still remains severe. As the National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital of the Zhejiang University School of Medicine is the primary medical care center for COVID-19 in Zhejiang Province. Based on the present expert consensus carried out by the National Health Commission and National Administration of Traditional Chinese Medicine, our team summarized and established an effective treatment strategy centered on "Four-Anti and Two-Balance" for clinical practice. The "Four-Anti and Two-Balance" strategy includes antivirus, anti-shock, antihypoxemia, and anti-secondary infection, and maintaining of water, electrolyte and acid/base balance and microecological balance. Simultaneously, an integrated multidisciplinary personalized treatment is recommended to improve therapeutic effects. The importance of early viral detection, dynamic monitoring of inflammatory indexes, and chest radiographs has been emphasized in clinical decision-making. Sputum was observed with the highest positive rate by reverse transcription-polymerase chain reaction (RTPRC). Viral nucleic acids could be detected in 10% of the patients' blood samples at the acute phase and 50% of patients had positive RT-PCR results in their feces. We also isolated live viral strains from feces, indicating potential infectiousness of feces. Dynamic cytokine detection was necessary to timely identify cytokine storms and for the application of the artificial liver blood purification system. The "Four-Anti and Two-Balance" strategy effectively increased cure rates and reduced mortality. Early antiviral treatment alleviated disease severity and prevented illness progression. We found that lopinavir/ritonavir combined with abidol showed antiviral effects against COVID-19. Shock and hypoxemia were usually caused by cytokine storms. The artificial liver blood purification system was able to rapidly remove inflammatory mediators and block the cytokine storm. Moreover, it also contributed to the balance of fluids, electrolytes, and acids/bases and thus improved treatment efficacy during critical illness. For cases of severe illness, early and also short periods of moderate glucocorticoid administration was supported. Patients with an oxygenation index below 200mmHg were transferred to the intensive care unit. Conservative oxygen therapy was preferred and noninvasive ventilation (NIV) was not recommended. Patients with mechanical ventilation were strictly supervised with cluster ventilator-associated pneumonia prevention strategies. Antimicrobial prophylaxis was prescribed rationally and was not recommended, except for patients with a long course of disease, repeated fever, and elevated procalcitonin, similarly secondary fungal infections were of concern. Some patients with COVID-19 showed intestinal microbial dysbiosis with decreased genus such as Lactobacillus and Bifidobacterium. Nutritional and gastrointestinal function should; therefore, be assessed for all patients. Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infections due to bacterial translocation. Anxiety and fear were common in patients with COVID-19. Therefore, we established a dynamic assessment and warning for psychological crises. We also integrated Chinese medicine in the treatment to promote rehabilitation. We optimized nursing processes for severe patients to promote their rehabilitation. Since viral clearance patterns after severe acute respiratory syndrome coronavirus 2 infections remained unclear, 2 weeks quarantine for discharged patients was required, and a regular following-up was also needed. These Zhejiang experiences and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work is warranted to further improve strategies of prevention, diagnosis, and treatment for COVID-19.

The Significance of Revising Diagnosis and Treatment Plan for Reducing Missed Diagnosis of Novel Coronavirus Pneumonia

Retrospective analysis of the clinical features of outpatients with novel coronavirus in areas outside Wuhan, China

A Clinical Staging Proposal of the Disease Course over Time in Non-Severe Patients with Coronavirus Disease 2019.

Analysis of factors associated early diagnosis in coronavirus disease 2019 (COVID-19)

2019 Novel Coronavirus (2019-Ncov) and 2019-Ncov Pneumonia

Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China

Evolution and major changes of the diagnosis and treatment protocol for COVID‐19 patients in China 2020–2023

[Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer During Epidemic Novel Coronavirus Pneumonia].

Improving the Understanding of Diagnosis and Treatment of Novel Coronavirus Infection

Improving the early diagnosis of suspected patients with COVID-19: a retrospective study of 106 patients

Clinical Characteristics and Current Treatment of Critically Ill Patients with COVID-19 Outside Wuhan, China: A Multicenter, Retrospective, Observational Study

Early Antiviral Treatment Contributes to Alleviate the Severity and Improve the Prognosis of Patients with Novel Coronavirus Disease (COVID-19)

Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China

Interpretations of “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)”

Clinical Reports on Early Diagnosis of Novel Coronavirus (2019-nCoV) Pneumonia in Stealth Infected Patients

The differential diagnosis for novel coronavirus pneumonia and similar lung diseases in general hospitals

Clinical Characteristics and Therapeutic Procedure for Four Cases with 2019 Novel Coronavirus Pneumonia Receiving Combined Chinese and Western Medicine Treatment.

Progress in cognition of revised and updated' Guidelines for Diagnosis and Treatment of COVID-19'

Translation: Management of Coronavirus Disease 2019 (COVID-19): Experience in Zhejiang Province, China

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China

Potential Predictors for Disease Progression and Medication Evaluation of 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China